Fundraising Fox

Ascendis Pharma

also invests · investor profile

Denmark, DK · Founded 2007 · 1,437 employees on LinkedIn · 6 known investors

Ascendis Pharma is a biopharmaceutical company developing therapies for hormone-related disorders and rare diseases. The company focuses on long-acting therapeutic formulations to address endocrine and rare disease indications.

BiotechHealthtechMedical Devices

Founders & leadership

Ascendis Pharma was founded in 2007 by Jan Møller Mikkelsen.

JM
Jan Møller MikkelsenFounder, President and Chief Executive Officer
JH
James HealyNamed on SEC filing
GR
Grethe RasmussenNamed on SEC filing
HR
Harald RauNamed on SEC filing
RT
Rafa?le TordjmanNamed on SEC filing
MO
Martin OlinNamed on SEC filing
JM
Jan M?ller MikkelsenNamed on SEC filing
LS
Lotte S?nderbjergNamed on SEC filing
MA
Martin AusterNamed on SEC filing
JS
Jonathan SilversteinNamed on SEC filing
MW
Michael Wolff JensenNamed on SEC filing
MM
Michael MayerNamed on SEC filing

Investors · 6

Vivo Capital✓ verifiedPalo Alto · $10M – $50M
Aisling CapitalNew York
Avoro Capital AdvisorsNew York
Foresite CapitalWest Hollywood
RA CapitalBoston
Sofinnova VenturesMenlo Park · $100K – $15M

Reported raises · per SEC filings

Form D private placements

$60M disclosed across 1 round · 2014

▶$60MraisedDec 2014 · 11 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • James HealyDirector
  • Grethe RasmussenExecutive Officer
  • Harald RauExecutive Officer
  • Rafa?le TordjmanDirector
  • Martin OlinDirector
  • Jan M?ller MikkelsenExecutive Officer, Director
  • Lotte S?nderbjergExecutive Officer
  • Martin AusterExecutive Officer
  • Jonathan SilversteinDirector
  • Michael Wolff JensenExecutive Officer, Director
  • Michael MayerDirector
  • Edwin de GraafDirector
  • Thomas SolowayExecutive Officer
  • Albert ChaDirector
Offering amount
$60M
Amount sold
$60M
First sale
Nov 2014
Incorporated
Other, Denmark
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Medscape41 shared keywordsMedscape is an online medical information platform providing clinical news, expert perspectives, case studies, quizzes, and reference material across specialties such as cardiology, oncology, neurology, and psychiatry. It serves physicians, nurses, pharmacists, residents, and medical students.

Companies competing with Ascendis Pharma for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Dorsey Wright & Associates Acquires 3,375 Shares of Ascendis Pharma A/S $ASND - Daily Politicaldailypolitical.com · Jul 2026BofA raises Ascendis Pharma stock price target on revenue outlook By Investing.cominvesting.com · Jul 2026Ascendis Pharma (ASND) Stock Looks Above Fair Value As Shares Jump 24%finance.yahoo.com · Jul 2026Ascendis Pharma Closes Warrant Exercise Window, Expands Share Capital - TipRanks.comtipranks.com · Jun 2026Ascendis Pharma details warrant exercises, capital boost | ASND SEC Filing - Form 6-Kstocktitan.net · Jun 2026Ascendis Pharma jumps as investors weigh cash boost, pipeline momentum, and possible index-related buying | Quiver Quantitativequiverquant.com · Jun 2026

Frequently asked questions

What does Ascendis Pharma do?
Ascendis Pharma is a biopharmaceutical company developing therapies for hormone-related disorders and rare diseases. The company focuses on long-acting therapeutic formulations to address endocrine and rare disease indications.
Who founded Ascendis Pharma?
Ascendis Pharma was founded by Jan Møller Mikkelsen in 2007.
Who are Ascendis Pharma's investors?
Ascendis Pharma's investors include Vivo Capital, Aisling Capital, Avoro Capital Advisors, Foresite Capital, RA Capital, Sofinnova Ventures.
How much funding has Ascendis Pharma raised?
Ascendis Pharma has disclosed $60M raised across 1 round.
Where is Ascendis Pharma headquartered?
Ascendis Pharma is headquartered in Denmark, DK.